Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Non-Current Liabilities (2020 - 2022)

Historic Total Non-Current Liabilities for Ovid Therapeutics (OVID) over the last 3 years, with Q1 2022 value amounting to $26.1 million.

  • Ovid Therapeutics' Total Non-Current Liabilities rose 5967.0% to $26.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $26.1 million, marking a year-over-year increase of 5967.0%. This contributed to the annual value of $14.8 million for FY2021, which is 5417.61% down from last year.
  • Latest data reveals that Ovid Therapeutics reported Total Non-Current Liabilities of $26.1 million as of Q1 2022, which was up 5967.0% from $14.8 million recorded in Q4 2021.
  • Ovid Therapeutics' Total Non-Current Liabilities' 5-year high stood at $32.3 million during Q4 2020, with a 5-year trough of $10.1 million in Q3 2021.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $14.8 million (2020), whereas its average is $17.0 million.
  • Per our database at Business Quant, Ovid Therapeutics' Total Non-Current Liabilities plummeted by 5417.61% in 2021 and then soared by 5967.0% in 2022.
  • Ovid Therapeutics' Total Non-Current Liabilities (Quarter) stood at $32.3 million in 2020, then tumbled by 54.18% to $14.8 million in 2021, then skyrocketed by 76.37% to $26.1 million in 2022.
  • Its Total Non-Current Liabilities stands at $26.1 million for Q1 2022, versus $14.8 million for Q4 2021 and $10.1 million for Q3 2021.